[Ed. – Fly-by-night snake oil operation, that Cedars-Sinai crowd. One of the things Trump referred to in his comments on potential novel treatments as worth looking into,]
The research team at Cedars-Sinai is currently working with the FDA to explore an expedited regulatory process to use the treatment as a possible medical intervention for those suffering from the Wuhan coronavirus.
[Aytu BioScience, Inc. (the “Company”)], a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has signed an exclusive worldwide license from Cedars-Sinai to develop and commercialize the Healight Platform Technology (“Healight”). This medical device technology platform, discovered and developed by scientists at Cedars-Sinai, is being studied as a potential first-in-class treatment for coronavirus and other respiratory infections.
The Healight technology employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical findings indicate the technology’s significant impact on eradicating a wide range of viruses and bacteria, inclusive of coronavirus.